Physician profile
Jon V Trankina
NPI 1447206164
$12,972.06
in general payments reported to CMS, 2019-2025
40 companies · $3,012 in 2025
The $3,012 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $812 · 2021: $1,380 · 2022: $1,467 · 2023: $2,463 · 2024: $2,755 · 2025: $3,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,198 · Education: $33.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,197.53 |
| Education | $33.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,301.90 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,045.82 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $976.59 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $953.40 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Intercept Pharmaceuticals, INC. | $944.96 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $782.84 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $690.67 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $417.93 | 2023-2025 | Omvoh, Zepbound |
| Ironwood Pharmaceuticals, INC | $310.39 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $282.44 | 2019-2025 | Epclusa |
| Janssen Scientific Affairs, LLC | $280.36 | 2019-2023 | Stelara |
| Merck Sharp & Dohme LLC | $270.18 | 2019-2024 | Dificid, Zinplava |
| Novo Nordisk INC | $267.27 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $231.95 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $216.60 | 2023-2025 | Sucraid, Sucraid |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $215.58 | 2021-2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $196.89 | 2024-2025 | Terlivaz |
| Nestle Healthcare Nutrition INC. | $165.58 | 2021-2023 | |
| Medtronic USA, INC. | $148.19 | 2019 | |
| Madrigal Pharmaceuticals | $143.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $129.23 | 2024-2025 | Zenpep |
| Ethicon US, LLC | $125.00 | 2020 | |
| Phathom Pharmaceuticals, INC. | $105.87 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $97.63 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $94.56 | 2024-2025 | Iqirvo |
| Merz North America, INC. | $92.50 | 2023 | Xeomin |
| Pfizer INC. | $81.52 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $59.71 | 2023 | Dupixent |
| Ucb, INC. | $57.18 | 2019-2020 | |
| Celltrion USA INC. | $50.63 | 2024-2025 | Zymfentra, Vegzelma |
| Ferring Pharmaceuticals INC. | $39.48 | 2020-2021 | |
| Boston Scientific Corporation | $39.09 | 2019-2021 | |
| Alfasigma USA, INC. | $31.13 | 2020-2021 | |
| Allergan, INC. | $22.17 | 2019 | |
| Inspire Medical Systems, INC. | $19.44 | 2025 | Inspire |
| Vivus LLC | $19.14 | 2021 | |
| Braintree Laboratories, INC. | $18.24 | 2020 | |
| Axonics, INC. | $18.24 | 2024 | Axonics |
| Evoke Pharma, INC. | $15.01 | 2022 | |
| Redhill Biopharma INC. | $13.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Trankina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.